Fate of new cancer drug is uncertain in Netherlands, as institute deems it too costlyBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h6778 (Published 15 December 2015) Cite this as: BMJ 2015;351:h6778
- Pieter van Eijsden
The future of a newly licensed drug to treat lung cancer hangs in the balance in the Netherlands after the country’s National Health Care Institute (ZIN) found that its cost would be €134 000 (£97 000; $150 000) per quality adjusted life year (QALY) saved. This would be the first time in the Netherlands for a drug not to be reimbursed for financial reasons.
Nivolumab, which is used to treat squamous cell lung cancer, is made by Bristol-Myers Squibb and until now has been provided free by the company. It was approved by the European …
Log in using your username and password
Log in through your institution
Sign up for a free trial